CureVac and GSK COVID-19 vaccine shows promise in pre-clinical study
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated…
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.